Revance Logo
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
ABOUTLEADERSHIPBOARDPARTNERSHIPS
SUSTAINABILITYMEDICAL EDUCATIONAL GRANTSINVESTIGATOR SPONSORED TRIALS
Company
INVESTOR RELATIONSPRESS RELEASESEVENTS + PRESENTATIONSFINANCIALS & FILINGSCORPORATE GOVERNANCE
STOCK INFORMATIONANALYST COVERAGEINVESTOR FAQSCONTACT US
Investors
OPPORTUNITIESCULTUREBENEFITS
Careers
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
Facebook logoInstagram logoTwitter logoLinkedIn logo
1222 Demonbreun St
20th Floor
Nashville, TN 37203
+1 (510) 742-3400
LoginContact Revance
Back
January 26, 2017
BELMONT Phase 2 Clinical Data to be Presented at IMCAS World Congress 2017
January 18, 2017
Revance Presents Clinical Data for RT002 Injectable at TOXINS 2017
January 5, 2017
Revance Provides Clinical Milestones and Financial Outlook for 2017
December 12, 2016
Revance Announces Positive 24-Week Duration of Effect in Interim Results from Phase 2 Cervical Dystonia Trial
December 7, 2016
Revance Announces Initiation of Subject Dosing in the SAKURA Phase 3 Clinical Program of RT002 Injectable for the Treatment of Glabellar (Frown) Lines
November 17, 2016
Revance to Participate in the 28th Annual Piper Jaffray Healthcare Conference
November 7, 2016
Revance to Participate in the Jefferies 2016 London Healthcare Conference
November 3, 2016
Revance Releases Third Quarter 2016 Results
November 3, 2016
Revance Announces Initiation of Phase 2 Trial of RT002 Injectable to Treat Plantar Fasciitis
October 24, 2016
Revance Therapeutics to Release Third Quarter 2016 Financial Results Thursday, November 3, 2016
Displaying 191 - 200 of 280